Table 3 Utilization of JAK inhibitors in clinical trials
Leukemia Subtype | Clinical trial | Phase | JAK Inhibitor |
|---|---|---|---|
AML | NCT04282187 | 2 | Ruxolitinib |
AML | NCT02532010 | 2 | Pacritinib |
AML | NCT02323607 | 1 | Pacritinib |
AML | NCT03878199 | 2 | Ruxolitinib |
AML | NCT04282187 | 2 | Pacritinib |
AML | NCT01620216 | 2 | Pacritinib |
AML | NCT03874052 | 1 | Ruxolitinib |
ALL | NCT02723994 | 2 | Ruxolitinib |
CLL | NCT03041636 | 2 | Ruxolitinib |
CLL | NCT02677948 | 2 | Pacritinib |
CLL | NCT03601819 | 1 | Pacritinib |
CML | NCT01751425 | 1 | Ruxolitinib |
CML | NCT03654768 | 2 | Ruxolitinib |
CML | NCT05127174 | 2 | Fedratinib |
CML | NCT04955938 | 1 | Fedratinib |
CML | NCT02564536 | 1 | Pacritinib |
CML | NCT02469415 | 2 | Pacritinib |
TCLGLL | NCT05592015 | 2 | Ruxolitinib |
ATCL | NCT01712659 | 2 | Ruxolitinib |
TKI Resistant Philadelphia Leukemia | NCT01914484 | 2 | ​Ruxolitinb |
AML ALL CLL | NCT00674479 | 2 | Ruxolitinib |